Newsfeed | Navigating EGFR

MiR-668-3p in M2 macrophage-derived exosomes activates autophagy through the ETS1/EGFR axis and promotes cisplatin resistance in gastric cancer

Read more about MiR-668-3p in M2 macrophage-derived exosomes activates autophagy through the ETS1/EGFR axis and promotes cisplatin resistance in gastric cancer

AbstractBackground Previous research suggests that tumor-associated macrophages (TAMs) influence the cisplatin (DDP) tolerance of gastric cancer (GC) cells via the secretion of microRNA-containing exosomes. This study aims to investigate the role of exosomal miR-668-3p from M2 macrophages in modulating DDP...

FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer

Read more about FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer

By Lori Solomon HealthDay Reporter Medically reviewed by Drugs.com via HealthDay TUESDAY, Dec. 23, 2025 -- The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with...

Simcere Wins NMPA Nod to Start Clinical Trials for Novel EGFR/cMET Cancer Drug

Read more about Simcere Wins NMPA Nod to Start Clinical Trials for Novel EGFR/cMET Cancer Drug

The latest update is out from Simcere Pharmaceutical Group Limited ( ($HK:2096) ). Simcere Pharmaceutical Group Limited has received approval from China’s National Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools...

Study Examines Clinicopathologic Characteristics and Treatment Outcomes in NSCLC Patients with EGFR and ALK Mutations

Read more about Study Examines Clinicopathologic Characteristics and Treatment Outcomes in NSCLC Patients with EGFR and ALK Mutations

Study Examines Clinicopathologic Characteristics and Treatment Outcomes in NSCLC Patients with EGFR and ALK Mutations Recent research has provided new insights into non-small cell lung cancer (NSCLC) linked to EGFR and ALK genetic alterations. A study conducted by Ding et...

Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation

Read more about Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation

AbstractBackground The aim of this study is to delineate clinicopathologic features, therapeutic outcomes, and tumor microenvironment (TME) remodeling in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor/anaplastic lymphoma kinase (EGFR/ALK) aberrations who experience histologic transformation (HT), with...

In-silico studies, synthesis, and pharmacological screening of novel multitarget diphenylpyrazole scaffold as EGFR/BRAF and cyclooxygenase-2 inhibitors

Read more about In-silico studies, synthesis, and pharmacological screening of novel multitarget diphenylpyrazole scaffold as EGFR/BRAF and cyclooxygenase-2 inhibitors

Multi-targeting drug design has become a prevalent attitude in exploring effective potent anticancer agents. In this regard, cyclooxygenase II (COX 2), tubulin, and focal adhesion kinase (FAK) are emerging as highly effective targets in the battle against cancer. Pyrazoles AS-(1–16)...

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Read more about ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential accelerated and full regulatory approvals NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE)...

Subscribe to Newsfeed